Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

Exclusion Criteria

• •Legal lower age limitations
• •Patients with symptomatic pulmonary embolism
• •Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT
• •Other indication for VKA than DVT
• •More than 36 hours before the treatment with therapeutic dosages of low molecular weight heparin or initiation of VKA treatment prior to randomization
• •Participation in another pharmacotherapeutic study within the prior 30 days
• •Creatinine clearance \<10mL/min, severe hepatic disease or bacterial endocarditis
• •Life expectancy \<3 Months
• •Active bleeding or high risk for bleeding
• •Uncontrolled hypertension: systolic blood pressure \>180 mm Hg and diastolic blood pressure \>110 mm Hg.
• •Pregnancy or childbearing potential without proper contraceptive measures
• •Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin (UFH), enoxaparin, or tinzaparin